Our quantitative flow cytometry and unbiased image analyses comprising EGF competitive inhibition and EGFR knockdown experiments demonstrate the specific uptake of K‐EGFRR by receptor‐mediated endocytosis in multiple EGFR‐positive cancer cell lines, making it an attractive candidate for targeted drug delivery. The gene discussed is EGF; the disease is cancer.